Chr	Start	End	Ref	Alt	Func.refGene	Gene.refGene	GeneDetail.refGene	ExonicFunc.refGene	AAChange.refGene	pLi.refGene	pRec.refGene	pNull.refGene	Disease_description.refGene	P(HI).refGene	P(rec).refGene	RVIS.refGene	RVIS_percentile.refGene	GDI.refGene	GDI-Phred.refGene	SIFT_score	SIFT_converted_rankscore	SIFT_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationAssessor_score	MutationAssessor_score_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST3_score	VEST3_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	CADD_raw	CADD_raw_rankscore	CADD_phred	DANN_score	DANN_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	Eigen_coding_or_noncoding	Eigen-raw	Eigen-PC-raw	GenoCanyon_score	GenoCanyon_score_rankscore	integrated_fitCons_score	integrated_fitCons_score_rankscore	integrated_confidence_value	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP20way_mammalian	phyloP20way_mammalian_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons20way_mammalian	phastCons20way_mammalian_rankscore	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	Interpro_domain	GTEx_V6_gene	GTEx_V6_tissue	Otherinfo
chr1	3421897	3421897	A	G	exonic	MEGF6	.	nonsynonymous SNV	MEGF6:NM_001409:exon17:c.T2063C:p.L688P	4.42E-15	0.994620434	0.005379566	.	0.11042	0.09881	2.072624965	97.81198396	6730.46373	17.39874	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.237	0.158	N	1	0.090	P	-1.3	0.007	N	2.57	0.136	T	5.68	0.000	N	0.032	0.452	-0.927	0.446	T	0.000	0.000	T	.	.	.	-0.904	0.036	0.025	0.046	0.000	0.007	0.029	N	c	-1.324	-1.215	1.000	0.500	0.507	0.198	0	2.53	0.295	1.398	0.339	0.076	0.183	0.004	0.165	0.070	0.176	8.044	0.295	EGF-like domain|EGF-like, conserved site|Growth factor receptor cysteine-rich domain|Laminin EGF domain;Laminin EGF domain	.	.	0.5	121	95	chr1	3421897	chr1:3421897	A	G	121	PASS	AN=2;DP=95	GT	0/1
chr1	16890428	16890428	T	A	UTR3	NBPF1	NM_017940:c.*10A>T	.	.	.	.	.	.	.	.	.	.	10963.86792	22.82724	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	79	126	chr1	16890428	chr1:16890428	T	A	79	PASS	AN=2;DP=126	GT	0/1
chr1	16952267	16952267	T	C	ncRNA_intronic	CROCCP2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	103	189	chr1	16952267	chr1:16952267	T	C	103	PASS	AN=2;DP=189	GT	0/1
chr1	17085030	17085030	C	T	exonic	MST1L	.	nonsynonymous SNV	MST1L:NM_001271733:exon11:c.G1445A:p.R482H	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	377	chr1	17085030	chr1:17085030	C	T	.	PASS	AN=0;DP=377	GT	0/1
chr1	17087459	17087459	A	G	exonic	MST1L	.	nonsynonymous SNV	MST1L:NM_001271733:exon2:c.T206C:p.M69T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	126	824	chr1	17087459	chr1:17087459	A	G	126	PASS	AN=2;DP=824	GT	0/1
chr1	17266616	17266616	A	G	intronic	CROCC	.	.	.	4.71E-20	0.643040868	0.356959132	.	.	0.15832	2.431142199	98.53149328	3783.54242	12.05321	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	131	191	chr1	17266616	chr1:17266616	A	G	131	PASS	AN=2;DP=191	GT	0/1
chr1	150526044	150526044	G	C	exonic	ADAMTSL4	.	nonsynonymous SNV	ADAMTSL4:NM_001288607:exon6:c.G577C:p.A193P,ADAMTSL4:NM_001288608:exon6:c.G577C:p.A193P,ADAMTSL4:NM_019032:exon6:c.G577C:p.A193P,ADAMTSL4:NM_025008:exon6:c.G577C:p.A193P	7.09E-16	0.34016242	0.65983758	DISEASE: Ectopia lentis 2, isolated, autosomal recessive (ECTOL2) [MIM:225100]: An ocular abnormality characterized by partial or complete displacement of the lens from its space resulting from defective zonule formation. {ECO:0000269|PubMed:19200529}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ectopia lentis et pupillae (ECTOLP) [MIM:225200]: An ocular abnormality characterized by displacement of the lenses and the pupils, associated with other ocular anomalies, but without systemic manifestations. The condition is usually bilateral, with the lenses and pupils displaced in opposite directions. Additional signs include enlarged corneal diameter, increased corneal astigmatism, increased anterior chamber depth, thinning and flattening of the iris with loss of crypts, angle malformation caused by enlarged iris processes, persistent pupillary membrane, loss of zonular fibers, tilted disk, and increased axial length. Secondary manifestations include refractive errors, glaucoma, early cataract development, and retinal detachment. Membrane formation on the posterior aspect of the iris has been observed both in histologic sections and on ultrasound biomicroscopy. {ECO:0000269|PubMed:20702823}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.10654	0.09865	-0.00377668	53.51497995	1103.99507	6.3513	0.703	0.076	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	P	-0.205	0.041	N	0.23	0.631	T	1.43	0.011	N	0.012	0.003	-1.058	0.123	T	0.031	0.132	T	.	.	.	-1.198	0.025	0.007	0.673	0.081	0.006	0.026	N	c	-1.688	-1.744	1.000	0.747	0.660	0.495	0	-4.57	0.032	-1.171	0.032	-1.198	0.016	0.000	0.063	0.007	0.100	3.170	0.061	.	ENSG00000143452.11|ENSG00000259357.1|ENSG00000163131.6|ENSG00000259357.1|ENSG00000259357.1|ENSG00000143452.11|ENSG00000259357.1|ENSG00000163131.6|ENSG00000143452.11|ENSG00000143369.10|ENSG00000259357.1|ENSG00000163131.6|ENSG00000259357.1|ENSG00000143452.11|ENSG00000237781.2|ENSG00000143382.9|ENSG00000259357.1|ENSG00000163131.6|ENSG00000143457.6|ENSG00000259357.1|ENSG00000259357.1|ENSG00000259357.1|ENSG00000259357.1|ENSG00000259357.1|ENSG00000163131.6|ENSG00000143452.11|ENSG00000259357.1|ENSG00000143457.6|ENSG00000259357.1|ENSG00000143452.11|ENSG00000259357.1|ENSG00000143457.6|ENSG00000143452.11|ENSG00000259357.1|ENSG00000143457.6|ENSG00000259357.1|ENSG00000143452.11|ENSG00000259357.1|ENSG00000259357.1	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Tibial|Breast_Mammary_Tissue|Breast_Mammary_Tissue|Cells_EBV-transformed_lymphocytes|Cells_Transformed_fibroblasts|Cells_Transformed_fibroblasts|Cells_Transformed_fibroblasts|Cells_Transformed_fibroblasts|Colon_Sigmoid|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Lung|Muscle_Skeletal|Muscle_Skeletal|Nerve_Tibial|Nerve_Tibial|Nerve_Tibial|Pancreas|Skin_Not_Sun_Exposed_Suprapubic|Skin_Not_Sun_Exposed_Suprapubic|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Spleen|Thyroid|Thyroid|Whole_Blood	0.5	150	111	chr1	150526044	chr1:150526044	G	C	150	PASS	AN=2;DP=111	GT	0/1
chr1	201178768	201178768	A	G	exonic	IGFN1	.	nonsynonymous SNV	IGFN1:NM_001164586:exon12:c.A4747G:p.S1583G	2.50E-18	0.007485788	0.992514212	.	0.12425	0.10243	6.487063031	99.87615004	12297.47943	23.82839	0.621	0.053	T	.	.	.	.	.	.	.	.	.	1	0.090	N	.	.	.	-1.03	0.764	T	0.67	0.023	N	0.016	0.013	-1.014	0.258	T	0.146	0.471	T	0.069	0.706	D	-2.098	0.007	0.001	0.770	0.113	0.001	0.004	N	c	-1.686	-1.819	0.000	0.035	0.487	0.133	0	-1.87	0.073	-1.095	0.034	-3.069	0.001	0.000	0.063	0.000	0.016	0.803	0.010	.	.	.	0.5	112	210	chr1	201178768	chr1:201178768	A	G	112	PASS	AN=2;DP=210	GT	0/1
chr1	207888640	207888640	-	T	intronic	CR1L	.	.	.	3.56E-15	0.020225564	0.979774436	.	0.06963	.	3.872389272	99.64614296	2178.56335	8.59961	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	64	61	chr1	207888640	chr1:207888640	C	CT	64	PASS	AN=2;DP=61	GT	0/1
chr1	227068322	227068322	A	C	intronic	PSEN2	.	.	.	0.027014182	0.961183973	0.011801844	DISEASE: Alzheimer disease 4 (AD4) [MIM:606889]: A familial early- onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. {ECO:0000269|PubMed:10631141, ECO:0000269|PubMed:10732806, ECO:0000269|PubMed:22503161, ECO:0000269|PubMed:7638622, ECO:0000269|PubMed:7651536, ECO:0000269|PubMed:9384602}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1V (CMD1V) [MIM:613697]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:17186461}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.64189	0.66407	-1.019530098	8.038452465	211.70746	3.13692	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	102	109	chr1	227068322	chr1:227068322	A	C	102	PASS	AN=2;DP=109	GT	0/1
chr1	236899900	236899900	C	-	exonic	ACTN2	.	frameshift deletion	ACTN2:NM_001278344:exon10:c.91delC:p.P32Lfs*11	0.999811916	0.000188084	7.39E-12	DISEASE: Cardiomyopathy, familial hypertrophic 23, with or without left ventricular non-compaction (CMH23) [MIM:612158]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:20022194, ECO:0000269|PubMed:25173926}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1AA, with or without left ventricular non-compaction (CMD1AA) [MIM:612158]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:14567970, ECO:0000269|PubMed:25224718}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.77327	0.39885	-1.723336008	2.465204058	447.74179	4.40066	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	109	45	chr1	236899899	chr1:236899899	TC	T	109	PASS	AN=2;DP=45	GT	0/1
chr1	242383170	242383170	-	AC	intronic	PLD5	.	.	.	0.124197737	0.874752709	0.001049554	.	0.21114	0.08983	-0.181750739	40.15687662	20.81668	0.70563	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	20	chr1	242383170	chr1:242383170	T	TAC	53	PASS	AN=2;DP=20	GT	0/1
chr2	15536509	15536509	-	A	intronic	NBAS	.	.	.	1.89E-25	0.999906723	9.33E-05	DISEASE: Infantile liver failure syndrome 2 (ILFS2) [MIM:616483]: A form of infantile liver failure syndrome, a life-threatening disorder of hepatic function that manifests with acute liver failure in the first few months of life. Clinical features include anemia, renal tubulopathy, developmental delay, seizures, failure to thrive, and liver steatosis and fibrosis. {ECO:0000269|PubMed:26073778}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=NBAS mutations have been found in a multisystem disease affecting the liver, eye, immune system, connective tissue, and bone. Clinical manifestations include a progeroid appearance, short stature, slender bones, epiphyseal dysplasia with multiple phalangeal pseudo-epiphyses, cervical instability, myelopathy, elevated transaminases, hypogammaglobulinemia, reduced natural killer cells, Pelger-Huet anomaly of granulocytes, and in some cases retinal dystrophy and optic atrophy. {ECO:0000269|PubMed:26286438}.; 	.	.	-0.224542487	37.33191791	2659.86206	9.69933	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	25	chr2	15536509	chr2:15536509	G	GA	50	PASS	AN=2;DP=25	GT	0/1
chr2	87169455	87169455	-	CGGCCTCGACCTGGCGGGGCGG	intronic	RGPD1;RGPD2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	107	198	chr2	87169455	chr2:87169455	A	ACGGCCTCGACCTGGCGGGGCGG	107	PASS	AN=2;DP=198	GT	0/1
chr2	89545096	89545096	G	C	intergenic	MIR4436A;NONE	dist=433128;dist=NONE	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	83	95	chr2	89545096	chr2:89545096	G	C	83	PASS	AN=2;DP=95	GT	0/1
chr2	96688929	96688929	G	A	exonic	GPAT2	.	nonsynonymous SNV	GPAT2:NM_001321529:exon18:c.C1879T:p.R627C,GPAT2:NM_001321530:exon18:c.C1861T:p.R621C,GPAT2:NM_001321525:exon19:c.C2092T:p.R698C,GPAT2:NM_001321526:exon19:c.C2092T:p.R698C,GPAT2:NM_001321527:exon19:c.C2092T:p.R698C,GPAT2:NM_207328:exon19:c.C2074T:p.R692C	0.0016123	0.992339401	0.006048299	.	.	.	.	.	151.08322	2.68731	0.0	0.912	D	0.584	0.541	P	0.093	0.419	B	0.019	0.272	N	0.996	0.810	D	2.545	0.745	M	-1.38	0.803	T	-3.74	0.710	D	0.582	0.614	-0.949	0.412	T	0.008	0.029	T	.	.	.	5.499	0.747	26.2	0.998	0.926	0.830	0.418	D	c	0.320	0.409	0.270	0.189	0.713	0.817	0	5.44	0.793	2.136	0.415	1.013	0.643	1.000	0.715	0.999	0.750	16.748	0.853	.	.	.	0.5	125	156	chr2	96688929	chr2:96688929	G	A	125	PASS	AN=2;DP=156	GT	0/1
chr2	101437601	101437601	C	G	intronic	NPAS2	.	.	.	0.990888562	0.009111438	7.90E-10	.	0.21897	0.22837	-0.506987379	21.76810569	5079.47281	14.59455	.	.	.	0.005	0.119	B	0.003	0.080	B	.	.	.	1	0.090	P	.	.	.	0.78	0.494	T	.	.	.	0.089	0.086	-0.993	0.318	T	0.000	0.000	T	.	.	.	0.932	0.183	10.26	0.684	0.084	0.123	0.170	N	c	-0.944	-0.949	1.000	0.747	0.437	0.062	0	2.43	0.287	0.288	0.186	0.852	0.362	0.003	0.159	0.015	0.124	7.284	0.253	.	ENSG00000170485.12	Skin_Sun_Exposed_Lower_leg	0.5	147	78	chr2	101437601	chr2:101437601	C	G	147	PASS	AN=2;DP=78	GT	1/0
chr2	120857746	120857747	TA	-	intronic	EPB41L5	.	.	.	0.022933841	0.977065093	1.07E-06	.	0.19351	0.09111	0.04598748	57.47817882	253.06645	3.42227	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	101	18	chr2	120857745	chr2:120857745	GTA	G	101	PASS	AN=2;DP=18	GT	1/0
chr2	166810161	166810161	-	CCCGCCCGCTCA	intronic	TTC21B	.	.	.	3.39E-22	0.098887146	0.901112854	DISEASE: Note=Ciliary dysfunction leads to a broad spectrum of disorders, collectively termed ciliopathies. Overlapping clinical features include retinal degeneration, renal cystic disease, skeletal abnormalities, fibrosis of various organ, and a complex range of anatomical and functional defects of the central and peripheral nervous system. The ciliopathy range of diseases includes Meckel-Gruber syndrome, Bardet-Biedl syndrome, Joubert syndrome, nephronophtisis, Senior-Loken syndrome, and Jeune asphyxiating thoracic dystrophy among others. TTC21B is causally associated with diverse ciliopathies, and also acts as a modifier gene across the ciliopathy spectrum. TTC21B mutations interact in trans with mutations in other ciliopathy-causing genes and contribute to disease manifestation and severity.; DISEASE: Nephronophthisis 12 (NPHP12) [MIM:613820]: An autosomal recessive disorder resulting in end-stage renal disease. It is a progressive tubulo-interstitial kidney disorder histologically characterized by modifications of the tubules with thickening of the basement membrane, interstitial fibrosis and, in the advanced stages, medullary cysts. Some patients manifest extra-renal features including retinal, skeletal and central nervous system defects. {ECO:0000269|PubMed:21258341}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Short-rib thoracic dysplasia 4 with or without polydactyly (SRTD4) [MIM:613819]: A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome. {ECO:0000269|PubMed:21258341}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bardet-Biedl syndrome (BBS) [MIM:209900]: A syndrome characterized by usually severe pigmentary retinopathy, early- onset obesity, polydactyly, hypogenitalism, renal malformation and mental retardation. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease. {ECO:0000269|PubMed:21258341}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Joubert syndrome 11 (JBTS11) [MIM:613820]: A disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy and renal disease. {ECO:0000269|PubMed:21258341, ECO:0000269|PubMed:22425360}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; 	0.13531	0.09894	0.619029743	83.25666431	820.66154	5.62646	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	122	94	chr2	166810161	chr2:166810161	G	GCCCGCCCGCTCA	122	PASS	AN=2;DP=94	GT	0/1
chr2	226265720	226265722	TGG	-	UTR5	NYAP2	NM_020864:c.-7877_-7875del-	.	.	0.906196258	0.093772035	3.17E-05	.	.	.	-0.020150552	52.25288983	158.7708	2.75169	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	131	47	chr2	226265719	chr2:226265719	CTGG	C	131	PASS	AN=2;DP=47	GT	0/1
chr3	121515941	121515941	T	-	intronic	IQCB1	.	.	.	1.20E-07	0.985796861	0.014203019	DISEASE: Senior-Loken syndrome 5 (SLSN5) [MIM:609254]: A renal- retinal disorder characterized by progressive wasting of the filtering unit of the kidney (nephronophthisis), with or without medullary cystic renal disease, and progressive eye disease. Typically this disorder becomes apparent during the first year of life. {ECO:0000269|PubMed:15723066}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.16973	0.17555	0.598963042	82.7789573	3536.66111	11.47062	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	25	chr3	121515940	chr3:121515940	AT	A	50	PASS	AN=2;DP=25	GT	0/1
chr3	123456300	123456300	C	T	exonic	MYLK	.	nonsynonymous SNV	MYLK:NM_001321309:exon7:c.G151A:p.D51N,MYLK:NM_053025:exon8:c.G679A:p.D227N,MYLK:NM_053026:exon8:c.G679A:p.D227N,MYLK:NM_053027:exon8:c.G679A:p.D227N,MYLK:NM_053028:exon8:c.G679A:p.D227N	9.38E-06	0.999990574	4.70E-08	DISEASE: Aortic aneurysm, familial thoracic 7 (AAT7) [MIM:613780]: A disease characterized by permanent dilation of the thoracic aorta usually due to degenerative changes in the aortic wall. It is primarily associated with a characteristic histologic appearance known as 'medial necrosis' or 'Erdheim cystic medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance. {ECO:0000269|PubMed:21055718}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.23578	.	-0.323627113	30.93300307	6562.91179	17.06993	0.005	0.632	D	1.0	0.899	D	0.999	0.971	D	.	.	.	0.999	0.467	D	3.265	0.902	M	-1.44	0.808	T	-2.92	0.611	D	0.247	0.318	0.672	0.928	D	0.750	0.915	D	0.166	0.846	D	3.591	0.489	23.2	0.998	0.899	0.959	0.664	D	c	0.600	0.425	1.000	0.747	0.706	0.609	0	5.2	0.716	5.960	0.699	0.935	0.490	1.000	0.715	0.004	0.083	17.660	0.880	Immunoglobulin I-set|Immunoglobulin subtype 2|Immunoglobulin-like domain|Immunoglobulin-like fold	.	.	0.5	.	64	chr3	123456300	chr3:123456300	C	T	.	PASS	AN=0;DP=64	GT	0/1
chr3	132071600	132071600	G	C	exonic	ACPP	.	nonsynonymous SNV	ACPP:NM_001292037:exon8:c.G802C:p.D268H,ACPP:NM_001099:exon9:c.G901C:p.D301H,ACPP:NM_001134194:exon9:c.G901C:p.D301H	1.76E-07	0.64651458	0.353485244	.	0.18544	0.1556	-0.602450568	17.91106393	66.58925	1.68257	0.076	0.373	T	0.262	0.341	B	0.063	0.322	B	0.008	0.308	N	0.893	0.406	D	2.87	0.836	M	2.22	0.182	T	-2.26	0.543	N	0.362	0.423	-1.068	0.098	T	0.041	0.177	T	0.007	0.190	T	2.531	0.365	19.67	0.981	0.374	0.577	0.302	D	c	-0.147	-0.100	1.000	0.747	0.520	0.210	0	4.04	0.461	1.717	0.374	1.044	0.665	1.000	0.715	0.803	0.337	6.341	0.204	.	.	.	0.5	53	57	chr3	132071600	chr3:132071600	G	C	53	PASS	AN=2;DP=57	GT	0/1
chr3	149233665	149233665	-	TTG	intergenic	TM4SF4;WWTR1	dist=12484;dist=1351	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	86	53	chr3	149233665	chr3:149233665	T	TTTG	86	PASS	AN=2;DP=53	GT	0/1
chr3	183900836	183900836	G	A	intronic	AP2M1	.	.	.	0.993893174	0.006106649	1.77E-07	.	0.23681	0.247	-0.141298762	42.87567823	32.02466	1.00657	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	11	chr3	183900836	chr3:183900836	G	A	50	PASS	AN=2;DP=11	GT	0/1
chr3	186917751	186917751	C	G	exonic	RTP1	.	nonsynonymous SNV	RTP1:NM_153708:exon2:c.C685G:p.Q229E	0.563829726	0.423951854	0.01221842	.	0.79035	0.11684	0.064394823	58.84642604	2341.27335	8.96348	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.003	0.351	N	1	0.090	P	0.55	0.145	N	1.62	0.282	T	-0.48	0.154	N	0.056	0.039	-0.976	0.358	T	0.000	0.000	T	.	.	.	0.084	0.102	3.442	0.622	0.067	0.018	0.056	N	c	-0.780	-0.618	0.910	0.263	0.615	0.372	0	5.74	0.900	1.719	0.374	0.133	0.217	0.528	0.269	0.580	0.285	12.993	0.579	.	ENSG00000198491.3|ENSG00000175077.5	Artery_Aorta|Nerve_Tibial	0.5	88	48	chr3	186917751	chr3:186917751	C	G	88	PASS	AN=2;DP=48	GT	0/1
chr4	15724487	15724487	T	G	intronic	BST1	.	.	.	2.81E-08	0.291985673	0.708014299	.	0.1269	0.19823	0.861712133	88.6883699	1705.28413	7.61637	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	25	chr4	15724487	chr4:15724487	T	G	58	PASS	AN=2;DP=25	GT	0/1
chr4	141294814	141294814	G	C	exonic	SCOC	.	nonsynonymous SNV	SCOC:NM_001153484:exon1:c.G124C:p.V42L,SCOC:NM_001153552:exon1:c.G124C:p.V42L,SCOC:NM_001153663:exon1:c.G124C:p.V42L	0.280616506	0.631537689	0.087845805	.	0.3001	0.11229	0.701931997	85.34442085	698.26576	5.26029	0.036	0.433	D	0.001	0.067	B	0.001	0.040	B	0.167	0.031	N	1	0.197	P	1.04	0.263	L	.	.	.	-0.37	0.132	N	0.164	0.198	-1.089	0.057	T	0.000	0.001	T	.	.	.	1.962	0.297	15.98	0.586	0.059	0.236	0.219	N	c	-0.773	-0.755	1.000	0.747	0.442	0.072	0	3.31	0.369	1.416	0.341	1.048	0.713	0.007	0.175	0.003	0.074	6.448	0.209	.	ENSG00000153132.8|ENSG00000153132.8	Esophagus_Mucosa|Muscle_Skeletal	0.5	136	168	chr4	141294814	chr4:141294814	G	C	136	PASS	AN=2;DP=168	GT	0/1
chr5	180055849	180055849	T	G	intronic	FLT4	.	.	.	0.999936679	6.33E-05	4.32E-15	DISEASE: Lymphedema, hereditary, 1A (LMPH1A) [MIM:153100]: A chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment. {ECO:0000269|PubMed:10835628, ECO:0000269|PubMed:10856194, ECO:0000269|PubMed:16924388, ECO:0000269|PubMed:16965327, ECO:0000269|PubMed:17458866, ECO:0000269|PubMed:19289394, ECO:0000269|PubMed:26091405, ECO:0000269|PubMed:9817924}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring. {ECO:0000269|PubMed:11807987}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=Plays an important role in tumor lymphangiogenesis, in cancer cell survival, migration, and formation of metastases.; 	0.19958	0.23555	0.707220641	85.53314461	835.41804	5.65903	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	127	93	chr5	180055849	chr5:180055849	T	G	127	PASS	AN=2;DP=93	GT	0/1
chr6	15468723	15468729	GGGTGAG	-	intronic	JARID2	.	.	.	0.999862193	0.000137807	7.01E-13	.	0.98339	0.18221	-1.741783094	2.418023119	264.05908	3.48721	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	8	chr6	15468722	chr6:15468722	AGGGTGAG	A	58	PASS	AN=2;DP=8	GT	1/0
chr7	11521436	11521436	G	C	exonic	THSD7A	.	nonsynonymous SNV	THSD7A:NM_015204:exon7:c.C1996G:p.L666V	0.999280749	0.000719251	1.10E-16	.	0.27361	0.08944	-1.308377521	4.865534324	3259.76198	10.88292	0.082	0.332	T	0.995	0.657	D	0.951	0.672	D	0.000	0.843	D	1.000	0.537	D	1.54	0.390	L	0.73	0.507	T	-2.31	0.513	N	0.412	0.643	-0.889	0.491	T	0.200	0.557	T	0.026	0.495	D	4.447	0.595	24.2	0.998	0.877	0.960	0.667	D	c	0.140	0.132	0.023	0.135	0.707	0.730	0	3.16	0.353	2.020	0.404	-0.213	0.100	1.000	0.715	0.991	0.552	10.944	0.463	.	.	.	0.5	90	168	chr7	11521436	chr7:11521436	G	C	90	PASS	AN=2;DP=168	GT	0/1
chr7	21856068	21856068	C	G	intronic	DNAH11	.	.	.	.	.	.	DISEASE: Kartagener syndrome (KTGS) [MIM:244400]: An autosomal recessive disorder characterized by the association of primary ciliary dyskinesia with situs inversus. Clinical features include recurrent respiratory infections, bronchiectasis, infertility, and lateral transposition of the viscera of the thorax and abdomen. The situs inversus is most often total, although it can be partial in some cases (isolated dextrocardia or isolated transposition of abdominal viscera). {ECO:0000269|PubMed:12142464, ECO:0000269|PubMed:18022865, ECO:0000269|PubMed:25186273}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ciliary dyskinesia, primary, 7 (CILD7) [MIM:611884]: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia; reduced fertility is often observed in male patients due to abnormalities of sperm tails. Half of the patients exhibit randomization of left-right body asymmetry and situs inversus, due to dysfunction of monocilia at the embryonic node. Primary ciliary dyskinesia associated with situs inversus is referred to as Kartagener syndrome. {ECO:0000269|PubMed:12142464, ECO:0000269|PubMed:18022865}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.12513	0.12171	.	.	20704.35568	30.36052	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	89	37	chr7	21856068	chr7:21856068	C	G	89	PASS	AN=2;DP=37	GT	0/1
chr7	26576535	26576535	T	C	ncRNA_exonic	KIAA0087	.	.	.	.	.	.	.	.	.	.	.	17.91578	0.62616	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	108	39	chr7	26576535	chr7:26576535	T	C	108	PASS	AN=2;DP=39	GT	0/1
chr7	36465572	36465572	A	G	intronic	ANLN	.	.	.	0.923521452	0.076478547	1.29E-09	DISEASE: Focal segmental glomerulosclerosis 8 (FSGS8) [MIM:616032]: A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. {ECO:0000269|PubMed:24676636}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.52557	0.15234	-1.146380093	6.334041047	5386.34454	15.13898	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	46	33	chr7	36465572	chr7:36465572	A	G	46	PASS	AN=2;DP=33	GT	0/1
chr7	44080619	44080619	-	CTT	ncRNA_exonic	LINC00957	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	140	314	chr7	44080619	chr7:44080619	A	ACTT	140	PASS	AN=2;DP=314	GT	0/1
chr7	56149274	56149274	G	C	intronic	PHKG1	.	.	.	3.58E-10	0.170265638	0.829734362	.	0.17418	0.1871	-1.418232832	4.110639302	78.27585	1.86564	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	119	141	chr7	56149274	chr7:56149274	G	C	119	PASS	AN=2;DP=141	GT	0/1
chr7	63673455	63673455	-	T	intronic	ZNF735	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	11	chr7	63673455	chr7:63673455	C	CT	50	PASS	AN=2;DP=11	GT	0/1
chr7	64168649	64168649	T	G	exonic	ZNF107	.	nonsynonymous SNV	ZNF107:NM_001282360:exon3:c.T2078G:p.I693R,ZNF107:NM_001282359:exon4:c.T2174G:p.I725R,ZNF107:NM_001013746:exon5:c.T1967G:p.I656R,ZNF107:NM_016220:exon7:c.T1967G:p.I656R	7.59E-17	0.000568738	0.999431262	.	.	.	0.158037129	64.85020052	284.42435	3.61089	1.0	0.010	T	0.01	0.144	B	0.03	0.205	B	.	.	.	0.713	0.335	D	-1.22	0.008	N	2.68	0.124	T	-0.01	0.072	N	0.34	0.401	-0.943	0.421	T	0.006	0.021	T	0.005	0.119	T	0.149	0.108	4.131	0.765	0.111	0.000	0.001	N	c	-1.321	-1.277	0.001	0.073	0.706	0.609	0	-2.54	0.059	-0.920	0.041	-1.237	0.015	0.000	0.063	0.031	0.148	2.106	0.034	Zinc finger C2H2-type/integrase DNA-binding domain|Zinc finger, C2H2|Zinc finger, C2H2-like	.	.	0.5	59	24	chr7	64168649	chr7:64168649	T	G	59	PASS	AN=2;DP=24	GT	0/1
chr7	76069902	76069902	G	C	exonic	ZP3	.	nonsynonymous SNV	ZP3:NM_001110354:exon7:c.G1034C:p.R345T,ZP3:NM_007155:exon8:c.G881C:p.R294T	0.001596815	0.88505152	0.113351664	.	0.2396	0.20208	0.775339069	87.13729653	870.97448	5.74737	0.263	0.164	T	0.002	0.197	B	0.004	0.176	B	0.499	0.120	U	1	0.090	N	1.175	0.300	L	2.41	0.252	T	-2.4	0.527	N	0.034	0.346	-0.987	0.332	T	0.030	0.131	T	.	.	.	-1.381	0.020	0.003	0.447	0.034	0.042	0.097	N	c	-1.589	-1.705	0.999	0.386	0.644	0.439	0	-8.56	0.008	-0.279	0.084	-0.405	0.062	0.000	0.063	0.000	0.016	12.211	0.535	Zona pellucida domain	.	.	0.5	64	37	chr7	76069902	chr7:76069902	G	C	64	PASS	AN=2;DP=37	GT	0/1
chr7	103003182	103003182	G	C	exonic	PSMC2	.	nonsynonymous SNV	PSMC2:NM_002803:exon6:c.G472C:p.D158H	0.999210833	0.000789161	5.94E-09	.	0.86027	.	-0.273576253	33.97027601	6.07663	0.23004	0.0	0.912	D	1.0	0.899	D	0.999	0.916	D	0.000	0.843	D	1	0.810	D	4.065	0.972	H	-3.7	0.954	D	-6.16	0.902	D	0.841	0.850	1.082	0.989	D	0.946	0.982	D	0.351	0.923	D	6.638	0.911	32	0.997	0.771	0.998	0.993	D	c	1.055	0.992	1.000	0.747	0.732	0.924	0	5.49	0.809	9.844	0.983	1.048	0.713	1.000	0.715	1.000	0.888	19.729	0.962	.	.	.	0.5	108	111	chr7	103003182	chr7:103003182	G	C	108	PASS	AN=2;DP=111	GT	0/1
chr7	151505788	151505788	A	-	intronic	PRKAG2	.	.	.	0.977557429	0.022442395	1.77E-07	DISEASE: Wolff-Parkinson-White syndrome (WPWS) [MIM:194200]: A supernormal conduction disorder characterized by the presence of one or several accessory atrioventricular connections, which can lead to episodes of sporadic tachycardia. {ECO:0000269|PubMed:11407343, ECO:0000269|PubMed:11748095}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, familial hypertrophic 6 (CMH6) [MIM:600858]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. CMH6 patients present Wolff-Parkinson-White ventricular preexcitation, enlarged myocytes without myofiber disarray, and glycogen- containing cytosolic vacuoles within cardiomyocytes. {ECO:0000269|PubMed:11371514, ECO:0000269|PubMed:11827995}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Glycogen storage disease of heart lethal congenital (GSDH) [MIM:261740]: Rare disease which leads to death within a few weeks to a few months after birth, through heart failure and respiratory compromise. {ECO:0000269|PubMed:15877279}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.75824	0.19412	-0.867014353	10.72776598	322.64102	3.81555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	51	chr7	151505787	chr7:151505787	GA	G,GAA	76	PASS	AN=2;DP=51	GT	0/1
chr7	151505788	151505788	-	A	intronic	PRKAG2	.	.	.	0.977557429	0.022442395	1.77E-07	DISEASE: Wolff-Parkinson-White syndrome (WPWS) [MIM:194200]: A supernormal conduction disorder characterized by the presence of one or several accessory atrioventricular connections, which can lead to episodes of sporadic tachycardia. {ECO:0000269|PubMed:11407343, ECO:0000269|PubMed:11748095}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, familial hypertrophic 6 (CMH6) [MIM:600858]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. CMH6 patients present Wolff-Parkinson-White ventricular preexcitation, enlarged myocytes without myofiber disarray, and glycogen- containing cytosolic vacuoles within cardiomyocytes. {ECO:0000269|PubMed:11371514, ECO:0000269|PubMed:11827995}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Glycogen storage disease of heart lethal congenital (GSDH) [MIM:261740]: Rare disease which leads to death within a few weeks to a few months after birth, through heart failure and respiratory compromise. {ECO:0000269|PubMed:15877279}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.75824	0.19412	-0.867014353	10.72776598	322.64102	3.81555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	51	chr7	151505787	chr7:151505787	GA	G,GAA	76	PASS	AN=2;DP=51	GT	0/1
chr8	103665676	103665676	A	-	intronic	KLF10	.	.	.	0.003421767	0.834210438	0.162367795	.	0.62417	0.17296	0.374860183	75.43052607	239.0998	3.341	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.38	49	chr8	103665675	chr8:103665675	TA	T,TAA	10.38	PASS	AN=0;DP=49	GT	0/1/.
chr8	103665676	103665676	-	A	intronic	KLF10	.	.	.	0.003421767	0.834210438	0.162367795	.	0.62417	0.17296	0.374860183	75.43052607	239.0998	3.341	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.38	49	chr8	103665675	chr8:103665675	TA	T,TAA	10.38	PASS	AN=0;DP=49	GT	0/1/.
chr8	124822508	124822508	T	-	intronic	FAM91A1	.	.	.	0.515693527	0.484306207	2.67E-07	.	0.30469	.	-0.622676946	17.30950696	54.36063	1.47405	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	38	chr8	124822507	chr8:124822507	CT	C	74	PASS	AN=2;DP=38	GT	0/1
chr8	144464706	144464706	C	G	exonic	RHPN1	.	nonsynonymous SNV	RHPN1:NM_052924:exon15:c.C1898G:p.P633R	1.30E-06	0.822567716	0.177430984	.	0.10052	0.10074	-0.529034136	20.85987261	149.9984	2.67044	0.003	0.682	D	0.998	0.715	D	0.962	0.690	D	0.004	0.348	N	0.827	0.348	D	1.83	0.482	L	0.45	0.565	T	-2.55	0.551	D	0.669	0.679	-0.489	0.691	T	0.246	0.615	T	0.053	0.653	D	4.491	0.601	24.3	0.997	0.825	0.164	0.192	N	c	0.097	-0.050	0.998	0.368	0.696	0.567	0	3.89	0.439	-0.180	0.097	0.852	0.362	0.000	0.063	0.438	0.260	9.219	0.363	.	.	.	0.5	79	209	chr8	144464706	chr8:144464706	C	G	79	PASS	AN=2;DP=209	GT	0/1
chr8	144808652	144808652	G	A	exonic	FAM83H	.	synonymous SNV	FAM83H:NM_198488:exon5:c.C2979T:p.N993N	0.88482471	0.115121211	5.41E-05	.	0.27378	0.10604	.	.	1586.01963	7.36593	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	63	chr8	144808652	chr8:144808652	G	A	.	PASS	AN=0;DP=63	GT	0/1
chr8	145579950	145579950	-	CCGCTGACCCTGGCACGGCACAAGGGCCCCCACACCTCACGTGCCTGGCCACAACCCAGA	intronic	FBXL6	.	.	.	3.70E-06	0.810919383	0.189076922	.	0.09239	0.10079	-0.442665927	24.53408823	363.5906	4.03651	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	159	512	chr8	145579950	chr8:145579950	G	GCCGCTGACCCTGGCACGGCACAAGGGCCCCCACACCTCACGTGCCTGGCCACAACCCAGA	159	PASS	AN=2;DP=512	GT	0/1
chr8	145725599	145725599	G	A	intronic	PPP1R16A	.	.	.	0.047670337	0.947290127	0.005039535	.	0.16096	0.11053	-0.778825328	12.88039632	88.81106	2.02338	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	124	692	chr8	145725599	chr8:145725599	G	A	124	PASS	AN=2;DP=692	GT	0/1
chr9	66499664	66499664	C	T	ncRNA_exonic	PTGER4P2-CDK2AP2P2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	139	chr9	66499664	chr9:66499664	C	T	.	PASS	AN=0;DP=139	GT	0/1
chr9	66513792	66513792	C	G	ncRNA_exonic	LOC403323	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	98	chr9	66513792	chr9:66513792	C	G	76	PASS	AN=2;DP=98	GT	0/1
chr9	66553447	66553447	G	C	ncRNA_exonic	LOC403323;LOC728673	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	96	146	chr9	66553447	chr9:66553447	G	C	96	PASS	AN=2;DP=146	GT	0/1
chr9	67273446	67273446	G	A	ncRNA_intronic	AQP7P1	.	.	.	.	.	.	.	0.02901	0.081	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	107	215	chr9	67273446	chr9:67273446	G	A	107	PASS	AN=2;DP=215	GT	0/1
chr9	68429152	68429152	T	C	ncRNA_exonic	FRG1JP	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	89	65	chr9	68429152	chr9:68429152	T	C	89	PASS	AN=2;DP=65	GT	0/1
chr11	64715289	64715289	T	C	exonic	MAJIN	.	nonsynonymous SNV	MAJIN:NM_001037225:exon7:c.A352G:p.K118E,MAJIN:NM_001318808:exon7:c.A34G:p.K12E	.	.	.	.	.	.	.	.	.	.	0.04	0.421	D	0.827	0.440	P	0.442	0.440	B	0.003	0.355	N	0.570	0.810	D	1.055	0.270	L	.	.	.	-2.2	0.495	N	0.345	0.406	-0.885	0.494	T	0.116	0.411	T	0.005	0.142	T	2.011	0.303	16.28	0.991	0.522	0.311	0.240	N	c	-0.132	-0.149	0.923	0.267	0.497	0.185	0	4.77	0.603	0.355	0.198	1.007	0.626	0.009	0.180	0.610	0.290	10.864	0.459	.	.	.	0.5	60	136	chr11	64715289	chr11:64715289	T	C	60	PASS	AN=2;DP=136	GT	0/1
chr11	68133035	68133035	T	C	intronic	LRP5	.	.	.	0.99835557	0.00164443	2.44E-12	DISEASE: Vitreoretinopathy, exudative 4 (EVR4) [MIM:601813]: A disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. {ECO:0000269|PubMed:15024691, ECO:0000269|PubMed:15346351, ECO:0000269|PubMed:15981244, ECO:0000269|PubMed:16929062, ECO:0000269|PubMed:19324841, ECO:0000269|PubMed:20340138, ECO:0000269|PubMed:24715757}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteoporosis (OSTEOP) [MIM:166710]: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs. {ECO:0000269|PubMed:14727154, ECO:0000269|PubMed:15824851, ECO:0000269|PubMed:16234968}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Osteoporosis-pseudoglioma syndrome (OPPG) [MIM:259770]: A disease characterized by congenital or infancy-onset blindness and severe juvenile-onset osteoporosis and spontaneous fractures. Additional clinical manifestations may include microphthalmos, abnormalities of the iris, lens or vitreous, cataracts, short stature, microcephaly, ligamental laxity, mental retardation and hypotonia. {ECO:0000269|PubMed:11719191, ECO:0000269|PubMed:16252235, ECO:0000269|PubMed:16679074, ECO:0000269|PubMed:17437160, ECO:0000269|PubMed:18602879}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: High bone mass trait (HBM) [MIM:601884]: Rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings. {ECO:0000269|PubMed:11741193, ECO:0000269|PubMed:12015390, ECO:0000269|PubMed:15824861, ECO:0000269|PubMed:17295608}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Endosteal hyperostosis, Worth type (WENHY) [MIM:144750]: An autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity. {ECO:0000269|PubMed:12579474}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteopetrosis, autosomal dominant 1 (OPTA1) [MIM:607634]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is an autosomal dominant form characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate. {ECO:0000269|PubMed:12579474}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Van Buchem disease 2 (VBCH2) [MIM:607636]: VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels. {ECO:0000269|PubMed:12579474}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.07666	0.10394	-3.724445291	0.241802312	2445.60749	9.20072	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	162	134	chr11	68133035	chr11:68133035	T	C	162	PASS	AN=2;DP=134	GT	0/1
chr11	71507232	71507232	C	G	ncRNA_intronic	ALG1L9P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	148	200	chr11	71507232	chr11:71507232	C	G	148	PASS	AN=2;DP=200	GT	0/1
chr11	71507261	71507261	A	G	ncRNA_intronic	ALG1L9P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	178	205	chr11	71507261	chr11:71507261	A	G	178	PASS	AN=2;DP=205	GT	0/1
chr11	123893791	123893791	A	C	exonic	OR10G9	.	synonymous SNV	OR10G9:NM_001001953:exon1:c.A72C:p.P24P	0.007138452	0.531885237	0.460976311	.	0.05817	0.09497	3.688480395	99.5576787	1919.79326	8.06598	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	135	154	chr11	123893791	chr11:123893791	A	C	135	PASS	AN=2;DP=154	GT	0/1
chr12	85285725	85285725	C	G	exonic	SLC6A15	.	nonsynonymous SNV	SLC6A15:NM_018057:exon2:c.G175C:p.D59H,SLC6A15:NM_182767:exon2:c.G175C:p.D59H	0.002262596	0.994003974	0.003733431	.	0.12557	0.1124	0.068033485	59.0351498	70.72739	1.74982	0.035	0.682	D	0.902	0.478	P	0.687	0.518	P	0.002	0.373	N	1.000	0.810	D	1.79	0.469	L	-0.78	0.736	T	-3.36	0.759	D	0.306	0.455	-0.414	0.716	T	0.341	0.707	T	0.024	0.468	T	5.522	0.750	26.3	0.996	0.718	0.975	0.749	D	c	0.355	0.434	1.000	0.747	0.706	0.609	0	4.59	0.561	4.955	0.631	0.935	0.490	1.000	0.715	0.990	0.544	17.013	0.862	.	.	.	0.5	87	18	chr12	85285725	chr12:85285725	C	G	87	PASS	AN=2;DP=18	GT	1/0
chr13	19384053	19384053	A	C	intergenic	LINC00417;ANKRD20A9P	dist=69814;dist=1230	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	38	chr13	19384053	chr13:19384053	A	C	72	PASS	AN=2;DP=38	GT	0/1
chr13	80095144	80095144	T	-	intronic	NDFIP2	.	.	.	0.80187873	0.196982259	0.001139011	.	0.14456	0.10625	0.327131069	73.27199811	599.78046	4.95722	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	13	chr13	80095143	chr13:80095143	CT	C	47	PASS	AN=2;DP=13	GT	0/1
chr14	105412138	105412138	A	G	exonic	AHNAK2	.	nonsynonymous SNV	AHNAK2:NM_001350929:exon7:c.T9350C:p.L3117P,AHNAK2:NM_138420:exon7:c.T9650C:p.L3217P	.	.	.	.	0.0478	.	27.59634509	99.99410238	24654.11397	32.49932	0.114	0.286	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	P	-2.045	0.002	N	6.64	0.005	T	2.0	0.004	N	0.055	0.037	-1.036	0.187	T	0.001	0.002	T	.	.	.	0.084	0.102	3.433	0.304	0.017	0.001	0.005	N	c	-1.613	-1.536	0.000	0.061	0.476	0.093	0	2.59	0.300	-0.281	0.084	-0.582	0.045	0.000	0.063	0.000	0.016	5.350	0.152	.	.	.	0.5	116	117	chr14	105412138	chr14:105412138	A	G	116	PASS	AN=2;DP=117	GT	0/1
chr14	106206603	106206603	A	G	intergenic	ELK2AP;MIR4507	dist=67459;dist=117690	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	138	391	chr14	106206603	chr14:106206603	A	G	138	PASS	AN=2;DP=391	GT	0/1
chr14	106206606	106206606	A	G	intergenic	ELK2AP;MIR4507	dist=67462;dist=117687	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	142	386	chr14	106206606	chr14:106206606	A	G	142	PASS	AN=2;DP=386	GT	0/1
chr15	21051204	21051270	TCAGGTTTTCTGCTCTTCCTTTGTGGAATTAATCCATCATCACCATTGCCAGCACTGGCACCATTAG	-	exonic	POTEB;POTEB2;POTEB3	.	frameshift deletion	POTEB2:NM_001277303:exon9:c.1190_1256del:p.T397Kfs*38,POTEB:NM_001277304:exon9:c.1190_1256del:p.T397Kfs*38,POTEB3:NM_207355:exon10:c.1190_1256del:p.T397Kfs*38	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	62	chr15	21051203	chr15:21051203	TTCAGGTTTTCTGCTCTTCCTTTGTGGAATTAATCCATCATCACCATTGCCAGCACTGGCACCATTAG	T	60	PASS	AN=2;DP=62	GT	0/1
chr15	76074518	76074518	T	G	intergenic	MIR4313;UBE2Q2	dist=19862;dist=61109	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	113	59	chr15	76074518	chr15:76074518	T	G	113	PASS	AN=2;DP=59	GT	0/1
chr16	29376056	29376056	T	A	ncRNA_exonic	SNX29P2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr16	29376056	chr16:29376056	T	A	.	PASS	AN=0;DP=38	GT	0/1
chr16	53934612	53934612	G	C	intronic	FTO	.	.	.	0.011344576	0.986864609	0.001790815	DISEASE: Growth retardation, developmental delay, and facial dysmorphism (GDFD) [MIM:612938]: A severe polymalformation syndrome characterized by postnatal growth retardation, microcephaly, severe psychomotor delay, functional brain deficits and characteristic facial dysmorphism. In some patients, structural brain malformations, cardiac defects, genital anomalies, and cleft palate are observed. Early death occurs by the age of 3 years. {ECO:0000269|PubMed:19559399}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Obesity (OBESITY) [MIM:601665]: A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat. {ECO:0000269|PubMed:26287746}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. A pathogenic intronic FTO variation (rs1421085) disrupts an evolutionarily conserved motif for ARID5B binding. Loss of ARID5B binding results in overexpression of two genes distal to FTO, IRX3 and IRX5. IRX3 and IRX5 overexpression shifts pre-adipocytes differentiation from brown to white fat cells, resulting in increased lipid storage and loss of mitochondrial thermogenesis. {ECO:0000269|PubMed:26287746}.; 	0.42596	0.28005	-0.288341872	33.41589998	98.07425	2.14102	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	110	chr16	53934612	chr16:53934612	G	C	69	PASS	AN=2;DP=110	GT	0/1
chr16	88874632	88874632	C	G	exonic	CDT1	.	synonymous SNV	CDT1:NM_030928:exon10:c.C1587G:p.L529L	7.76E-09	0.14754679	0.852453202	DISEASE: Meier-Gorlin syndrome 4 (MGORS4) [MIM:613804]: A syndrome characterized by bilateral microtia, aplasia/hypoplasia of the patellae, and severe intrauterine and postnatal growth retardation with short stature and poor weight gain. Additional clinical findings include anomalies of cranial sutures, microcephaly, apparently low-set and simple ears, microstomia, full lips, highly arched or cleft palate, micrognathia, genitourinary tract anomalies, and various skeletal anomalies. While almost all cases have primordial dwarfism with substantial prenatal and postnatal growth retardation, not all cases have microcephaly, and microtia and absent/hypoplastic patella are absent in some. Despite the presence of microcephaly, intellect is usually normal. {ECO:0000269|PubMed:21358631, ECO:0000269|PubMed:21358632}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.96985	0.14861	1.18495331	92.84029252	248.60148	3.39744	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	99	174	chr16	88874632	chr16:88874632	C	G	99	PASS	AN=2;DP=174	GT	0/1
chr17	21216846	21216846	G	C	exonic	MAP2K3	.	synonymous SNV	MAP2K3:NM_002756:exon11:c.G870C:p.L290L,MAP2K3:NM_145109:exon11:c.G957C:p.L319L,MAP2K3:NM_001316332:exon12:c.G870C:p.L290L	0.000496053	0.968531857	0.03097209	DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.; 	0.23537	0.33997	0.108486928	61.90728946	81.19169	1.90782	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	146	144	chr17	21216846	chr17:21216846	G	C	146	PASS	AN=2;DP=144	GT	0/1
chr18	49208	49208	G	A	intergenic	LOC102723376;ROCK1P1	dist=33278;dist=59857	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	-1.25	0.791	T	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.269	0.120	5.391	0.711	0.092	0.191	0.203	N	n	-0.126	-0.174	0.000	0.012	0.554	0.283	0	0.109	0.138	-0.406	0.072	0.344	0.273	0.844	0.301	0.001	0.043	2.943	0.054	.	.	.	0.5	98	105	chr18	49208	chr18:49208	G	A	98	PASS	AN=2;DP=105	GT	0/1
chr18	43577703	43577703	G	A	intronic	PSTPIP2	.	.	.	0.107611557	0.892114743	0.0002737	.	0.08446	0.08464	0.060756528	58.52795471	1683.83562	7.56284	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	78	224	chr18	43577703	chr18:43577703	G	A	78	PASS	AN=2;DP=224	GT	0/1
chr18	59217504	59217504	T	A	intronic	CDH20	.	.	.	0.980513136	0.019486247	6.16E-07	.	0.41102	0.0974	-0.619039275	17.39797122	686.47702	5.2313	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	107	41	chr18	59217504	chr18:59217504	T	A	107	PASS	AN=2;DP=41	GT	0/1
chr19	4511284	4511284	A	G	exonic	PLIN4	.	synonymous SNV	PLIN4:NM_001080400:exon3:c.T2646C:p.D882D	1.66E-12	0.007710433	0.992289567	.	0.16259	0.102	5.994578529	99.85845718	9818.87991	21.57786	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	82	111	chr19	4511284	chr19:4511284	A	G	82	PASS	AN=2;DP=111	GT	0/1
chr19	11132340	11132340	C	T	intronic	SMARCA4	.	.	.	0.999999998	2.39E-09	4.32E-23	DISEASE: Mental retardation, autosomal dominant 16 (MRD16) [MIM:614609]: A disease characterized by multiple congenital anomalies and mental retardation. Mental retardation is defined by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD16 patients manifest developmental delay, absent or hypoplastic fifth fingernails or toenails, thick eyebrows and long eyelashes, hirsutism. Additional findings include hypotonia, microcephaly, seizures, a Dandy-Walker malformation, and vision and hearing problems. {ECO:0000269|PubMed:22426308}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99989	0.50628	-2.851950648	0.601556971	107.64396	2.2526	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	163	chr19	11132340	chr19:11132340	C	T	.	PASS	AN=0;DP=163	GT	0/1
chr19	11591325	11591325	C	-	intronic	ELAVL3	.	.	.	0.822602584	0.176556392	0.000841025	.	0.39015	0.23372	-0.780646273	12.77423921	9.21155	0.33694	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	92	368	chr19	11591324	chr19:11591324	AC	A	92	PASS	AN=2;DP=368	GT	0/1
chr19	15918201	15918201	A	G	exonic	OR10H1	.	nonsynonymous SNV	OR10H1:NM_013940:exon1:c.T647C:p.L216P	0.637065116	0.334487775	0.028447109	.	0.15432	0.095	0.575097644	82.1656051	2707.23222	9.78935	0.008	0.586	D	0.997	0.689	D	0.976	0.719	D	0.012	0.295	N	0.937	0.372	D	3.125	0.882	M	8.34	0.003	T	-4.7	0.798	D	0.67	0.680	-0.686	0.611	T	0.002	0.006	T	0.005	0.127	T	4.839	0.650	24.8	0.999	0.930	0.163	0.191	N	c	0.497	0.355	0.001	0.086	0.487	0.133	0	4.96	0.650	2.769	0.471	0.897	0.411	0.014	0.188	0.989	0.536	12.564	0.555	GPCR, rhodopsin-like, 7TM	.	.	0.5	132	98	chr19	15918201	chr19:15918201	A	G	132	PASS	AN=2;DP=98	GT	0/1
chr19	15918238	15918238	A	C	exonic	OR10H1	.	nonsynonymous SNV	OR10H1:NM_013940:exon1:c.T610G:p.C204G	0.637065116	0.334487775	0.028447109	.	0.15432	0.095	0.575097644	82.1656051	2707.23222	9.78935	0.097	0.309	T	0.998	0.715	D	0.984	0.745	D	0.000	0.537	D	0.955	0.379	D	-1.47	0.005	N	1.29	0.358	T	-1.92	0.446	N	0.469	0.519	-1.046	0.155	T	0.021	0.086	T	.	.	.	1.099	0.200	11.21	0.865	0.160	0.091	0.148	N	c	-0.196	-0.226	0.017	0.129	0.554	0.283	0	4.71	0.589	2.526	0.450	0.897	0.411	0.402	0.260	0.068	0.175	10.575	0.442	GPCR, rhodopsin-like, 7TM	.	.	0.5	143	106	chr19	15918238	chr19:15918238	A	C	143	PASS	AN=2;DP=106	GT	0/1
chr19	33490585	33490585	G	A	exonic	RHPN2	.	stopgain	RHPN2:NM_033103:exon10:c.C1132T:p.Q378X	0.000336631	0.997287291	0.002376078	.	0.1907	0.10228	0.003714825	54.06935598	5254.99892	14.95444	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	12.292	0.982	39	0.998	0.910	0.991	0.907	D	c	1.043	0.881	1.000	0.747	0.672	0.522	0	4.72	0.591	9.105	0.935	0.889	0.393	1.000	0.715	0.979	0.486	17.685	0.881	BRO1 domain	.	.	0.5	109	115	chr19	33490585	chr19:33490585	G	A	109	PASS	AN=2;DP=115	GT	0/1
chr19	40368733	40368733	G	C	exonic	FCGBP	.	synonymous SNV	FCGBP:NM_003890:exon28:c.C12615G:p.L4205L	.	.	.	.	0.54275	.	.	.	18359.5916	28.93384	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	136	339	chr19	40368733	chr19:40368733	G	C	136	PASS	AN=2;DP=339	GT	0/1
chr19	41062902	41062902	-	C	intronic	SPTBN4	.	.	.	.	.	.	.	0.16131	0.15197	-1.824619408	2.129039868	5101.64368	14.64602	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	144	89	chr19	41062902	chr19:41062902	A	AC	144	PASS	AN=2;DP=89	GT	0/1
chr19	41285972	41285972	C	G	exonic	RAB4B	.	stopgain	RAB4B:NM_016154:exon2:c.C65G:p.S22X	0.940202326	0.059554587	0.000243086	.	0.37331	0.11262	-0.538132194	20.26421326	2.81543	0.10018	.	.	.	.	.	.	.	.	.	0.000	0.843	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	11.035	0.972	37	0.994	0.638	0.988	0.864	D	c	1.153	1.008	1.000	0.747	0.732	0.924	0	5.38	0.772	7.846	0.851	0.807	0.329	1.000	0.715	1.000	0.888	17.959	0.889	P-loop containing nucleoside triphosphate hydrolase|Small GTP-binding protein domain	.	.	0.5	69	45	chr19	41285972	chr19:41285972	C	G	69	PASS	AN=2;DP=45	GT	0/1
chr19	45375202	45375202	C	G	exonic	NECTIN2	.	nonsynonymous SNV	NECTIN2:NM_001042724:exon3:c.C571G:p.P191A,NECTIN2:NM_002856:exon3:c.C571G:p.P191A	.	.	.	.	0.11419	0.17465	0.556689353	81.63481953	.	.	0.043	0.413	D	0.847	0.448	P	0.725	0.532	P	0.002	0.373	N	0.993	0.417	D	1.005	0.253	L	-0.79	0.737	T	-5.3	0.892	D	0.45	0.508	-0.417	0.715	T	0.379	0.736	T	0.030	0.525	D	1.601	0.254	13.85	0.991	0.528	0.352	0.250	N	c	0.046	0.003	0.810	0.243	0.672	0.522	0	4.42	0.526	0.679	0.248	0.932	0.445	0.227	0.244	0.877	0.367	12.389	0.545	CD80-like, immunoglobulin C2-set|Immunoglobulin-like domain|Immunoglobulin-like fold	.	.	0.5	128	107	chr19	45375202	chr19:45375202	C	G	128	PASS	AN=2;DP=107	GT	0/1
chr19	51274851	51274851	A	C	exonic	GPR32	.	nonsynonymous SNV	GPR32:NM_001506:exon1:c.A994C:p.T332P	7.91E-05	0.315038766	0.68488214	.	0.0893	.	0.108486928	61.90728946	99.68741	2.16289	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	N	-1.72	0.003	N	1.24	0.367	T	3.88	0.001	N	0.074	0.064	-0.995	0.312	T	0.030	0.131	T	.	.	.	-1.311	0.022	0.004	0.827	0.139	0.001	0.005	N	c	-1.513	-1.493	0.002	0.089	0.497	0.185	0	-0.781	0.104	0.074	0.144	-0.869	0.028	0.000	0.063	0.757	0.323	3.651	0.077	.	.	.	0.5	91	43	chr19	51274851	chr19:51274851	A	C	91	PASS	AN=2;DP=43	GT	0/1
chr19	51919120	51919120	A	G	UTR5	LOC100129083	NM_001256795:c.-159A>G	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	118	139	chr19	51919120	chr19:51919120	A	G	118	PASS	AN=2;DP=139	GT	0/1
chr19	53990021	53990021	A	G	intronic	ZNF813	.	.	.	8.50E-10	0.079646859	0.92035314	.	0.08121	.	1.35769336	94.43854683	2208.34827	8.65139	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	141	99	chr19	53990021	chr19:53990021	A	G	141	PASS	AN=2;DP=99	GT	0/1
chr20	13140618	13140618	T	-	intronic	SPTLC3	.	.	.	0.00275524	0.994428189	0.002816571	.	0.10462	0.1278	-0.224023033	37.4321774	214.55753	3.15939	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	68	25	chr20	13140617	chr20:13140617	CT	C	68	PASS	AN=2;DP=25	GT	0/1
chr20	29625873	29625873	A	C	ncRNA_exonic	FRG1BP;FRG1DP	.	.	.	.	.	.	.	.	.	.	.	.	.	0.002	0.721	D	0.837	0.444	P	0.783	0.556	P	0.000	0.843	D	1	0.810	D	.	.	.	.	.	.	-2.77	0.587	D	0.799	0.789	-0.879	0.499	T	0.181	0.529	T	.	.	.	3.765	0.509	23.4	0.993	0.591	0.844	0.432	D	c	0.345	0.056	0.999	0.397	0.675	0.547	0	1.68	0.231	1.417	0.342	0.675	0.295	1.000	0.715	0.098	0.188	7.376	0.258	Actin cross-linking	.	.	0.5	78	54	chr20	29625873	chr20:29625873	A	C	78	PASS	AN=2;DP=54	GT	0/1
chr20	29625895	29625895	G	A	ncRNA_exonic	FRG1BP;FRG1DP	.	.	.	.	.	.	.	.	.	.	.	.	.	0.001	0.784	D	0.552	0.363	P	0.369	0.417	B	0.000	0.843	D	1.000	0.588	D	.	.	.	.	.	.	-6.2	0.904	D	0.781	0.772	-0.738	0.586	T	0.181	0.529	T	.	.	.	2.983	0.419	22.2	0.998	0.854	0.915	0.534	D	c	-0.048	-0.115	1.000	0.500	0.675	0.547	0	1.68	0.231	8.688	0.909	0.597	0.287	1.000	0.715	0.392	0.253	9.356	0.371	Actin cross-linking	.	.	0.5	84	54	chr20	29625895	chr20:29625895	G	A	84	PASS	AN=2;DP=54	GT	0/1
chr20	43976991	43976991	A	G	exonic	SDC4	.	nonsynonymous SNV	SDC4:NM_002999:exon1:c.T34C:p.F12L	0.011803491	0.847335334	0.140861176	.	0.26113	0.20685	-0.161524709	41.6430762	2463.14431	9.23969	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	0.354	0.043	N	1	0.588	P	-1.905	0.002	N	1.72	0.266	T	1.24	0.010	N	0.044	0.024	-0.934	0.436	T	0.000	0.000	T	.	.	.	1.585	0.252	13.77	0.784	0.119	0.065	0.124	N	c	-1.092	-0.869	1.000	0.747	0.564	0.319	0	1.9	0.247	0.261	0.181	0.088	0.194	0.995	0.385	0.796	0.335	5.835	0.177	.	.	.	0.5	105	84	chr20	43976991	chr20:43976991	A	G	105	PASS	AN=2;DP=84	GT	0/1
chr20	46294828	46294828	T	C	intronic	SULF2	.	.	.	0.878046241	0.121953654	1.05E-07	.	0.1472	.	-1.591018721	3.084453881	835.17771	5.65739	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	73	85	chr20	46294828	chr20:46294828	T	C	73	PASS	AN=2;DP=85	GT	0/1
chr20	46294864	46294864	A	G	intronic	SULF2	.	.	.	0.878046241	0.121953654	1.05E-07	.	0.1472	.	-1.591018721	3.084453881	835.17771	5.65739	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	97	169	chr20	46294864	chr20:46294864	A	G	97	PASS	AN=2;DP=169	GT	0/1
chr20	58411528	58411528	G	A	intronic	PHACTR3	.	.	.	0.971713289	0.028286398	3.13E-07	.	0.42756	0.10156	-0.220384297	37.6032083	240.61752	3.35156	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	46	chr20	58411528	chr20:58411528	G	A	.	PASS	AN=0;DP=46	GT	0/1
chr20	62203414	62203414	T	C	intronic	HELZ2	.	.	.	1.26E-09	0.999300381	0.000699618	.	.	.	-0.147490202	42.30360934	4463.72358	13.40473	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	181	chr20	62203414	chr20:62203414	T	C	.	PASS	AN=0;DP=181	GT	0/1
chr22	21579692	21579692	A	G	exonic	GGT2	.	nonsynonymous SNV	GGT2:NM_001351304:exon6:c.T152C:p.L51S	0.80481651	0.190051731	0.005131759	.	.	0.11718	.	.	1425.85016	7.053	1.0	0.010	T	.	.	.	.	.	.	.	.	.	1.000	0.200	N	.	.	.	3.62	0.044	T	5.21	0.000	N	0.138	0.166	-0.931	0.441	T	0.003	0.009	T	.	.	.	-0.658	0.047	0.090	0.247	0.011	0.007	0.029	N	c	-1.088	-1.002	0.000	0.050	0.554	0.246	0	1.7	0.232	6.366	0.728	-0.114	0.115	1.000	0.715	0.314	0.240	6.475	0.211	Nucleophile aminohydrolases, N-terminal	.	.	0.5	76	93	chr22	21579692	chr22:21579692	A	G	76	PASS	AN=2;DP=93	GT	0/1
chr22	38203338	38203338	-	CCC	UTR3	H1F0	NM_005318:c.*1202_*1203insCCC	.	.	0.154802582	0.635588541	0.209608877	.	0.85024	0.20751	-0.053113545	49.38664779	8.17863	0.30157	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	106	52	chr22	38203338	chr22:38203338	T	TCCC	106	PASS	AN=2;DP=52	GT	0/1
chr22	42898666	42898666	C	-	ncRNA_intronic	SERHL	.	.	.	.	.	.	.	0.10684	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	110	117	chr22	42898665	chr22:42898665	GC	G	110	PASS	AN=2;DP=117	GT	0/1
chr22	50312802	50312818	CCCTCGACCTGGGCTCG	-	intronic	CRELD2	.	.	.	4.96E-08	0.220198053	0.779801898	.	0.23727	0.10908	0.801024817	87.65628686	1620.87519	7.44658	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	147	99	chr22	50312801	chr22:50312801	ACCCTCGACCTGGGCTCG	A	147	PASS	AN=2;DP=99	GT	0/1
chr22	51193798	51193798	G	A	intergenic	ACR;RPL23AP82	dist=10071;dist=1716	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	119	276	chr22	51193798	chr22:51193798	G	A	119	PASS	AN=2;DP=276	GT	0/1
chrX	39932250	39932250	C	G	exonic	BCOR	.	nonsynonymous SNV	BCOR:NM_001123383:exon4:c.G2349C:p.K783N,BCOR:NM_001123384:exon4:c.G2349C:p.K783N,BCOR:NM_001123385:exon4:c.G2349C:p.K783N,BCOR:NM_017745:exon4:c.G2349C:p.K783N	0.999945621	5.44E-05	8.78E-12	.	0.36796	0.1257	-3.028489223	0.507195093	113.75272	2.32443	0.002	0.721	D	0.985	0.592	D	0.809	0.568	P	.	.	.	0.981	0.397	D	1.935	0.520	L	2.39	0.157	T	-1.77	0.535	N	0.083	0.077	-1.088	0.058	T	0.045	0.193	T	0.017	0.389	T	3.528	0.482	23.1	0.998	0.859	0.962	0.679	D	.	.	.	1.000	0.747	.	.	.	2.7	0.309	1.318	0.330	0.925	0.434	1.000	0.715	0.995	0.604	4.778	0.125	.	.	.	0.5	88	64	chrX	39932250	chrX:39932250	C	G	88	PASS	AN=2;DP=64	GT	0/1
chrX	86958351	86958351	A	G	intergenic	KLHL4;CPXCR1	dist=33301;dist=1043875	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	55	chrX	86958351	chrX:86958351	A	G	72	PASS	AN=2;DP=55	GT	0/1
chrX	122585463	122585463	G	A	intronic	GRIA3	.	.	.	0.998653778	0.001346218	4.42E-09	DISEASE: Mental retardation, X-linked 94 (MRX94) [MIM:300699]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non- syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. MRX94 patients have moderate mental retardation. Other variable features are macrocephaly, seizures, myoclonic jerks, autistic behavior, asthenic body habitus, distal muscle weakness and hyporeflexia. {ECO:0000269|PubMed:17989220}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.40491	0.17596	-0.115612493	45.12856806	18.51356	0.64055	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	77	chrX	122585463	chrX:122585463	G	A	.	PASS	AN=0;DP=77	GT	0/1
chrX	153287315	153287315	G	-	UTR3	MECP2	NM_004992:c.*8503delC	.	.	0.698089048	0.298098137	0.003812815	DISEASE: Angelman syndrome (AS) [MIM:105830]: A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue. {ECO:0000269|PubMed:11283202}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Mental retardation, X-linked, syndromic, 13 (MRXS13) [MIM:300055]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXS13 patients manifest mental retardation associated with other variable features such as spasticity, episodes of manic depressive psychosis, increased tone and macroorchidism. {ECO:0000269|PubMed:10986043, ECO:0000269|PubMed:11007980, ECO:0000269|PubMed:11309367, ECO:0000269|PubMed:11805248, ECO:0000269|PubMed:11885030, ECO:0000269|PubMed:12161600, ECO:0000269|PubMed:12325019, ECO:0000269|PubMed:12615169, ECO:0000269|PubMed:16966553}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Rett syndrome (RTT) [MIM:312750]: An X-linked dominant neurodevelopmental disorder, and one of the most common causes of mental retardation in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements, and develop microcephaly, seizures, autism, ataxia, mental retardation and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. {ECO:0000269|PubMed:10508514, ECO:0000269|PubMed:10577905, ECO:0000269|PubMed:10745042, ECO:0000269|PubMed:10767337, ECO:0000269|PubMed:10814719, ECO:0000269|PubMed:10944854, ECO:0000269|PubMed:10991688, ECO:0000269|PubMed:10991689, ECO:0000269|PubMed:11055898, ECO:0000269|PubMed:11241840, ECO:0000269|PubMed:11269512, ECO:0000269|PubMed:11283202, ECO:0000269|PubMed:11376998, ECO:0000269|PubMed:11402105, ECO:0000269|PubMed:11706982, ECO:0000269|PubMed:11738883, ECO:0000269|PubMed:12161600, ECO:0000269|PubMed:12567420, ECO:0000269|PubMed:12966522, ECO:0000269|PubMed:12966523, ECO:0000269|PubMed:15034579, ECO:0000269|PubMed:15057977}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Autism, X-linked 3 (AUTSX3) [MIM:300496]: A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate mental retardation. {ECO:0000269|PubMed:12770674}. Note=The disease may be caused by mutations affecting the gene represented in this entry.; DISEASE: Encephalopathy, neonatal severe, due to MECP2 mutations (ENS-MECP2) [MIM:300673]: A neurodevelopmental disorder characterized by severe neonatal encephalopathy, developmental delay, mental retardation, microcephaly, seizures. Additional features include respiratory insufficiency and central hypoventilation, gastroesophageal reflux, axial hypotonia, hyperreflexia and dyskinetic movements. {ECO:0000269|PubMed:11238684}. Note=The disease is caused by mutations affecting the gene represented in this entry. The MECP2 gene is mutated in Rett syndrome, a severe neurodevelopmental disorder that almost always occurs in females. Although it was first thought that MECP2 mutations causing Rett syndrome were lethal in males, later reports identified a severe neonatal encephalopathy in surviving male sibs of patients with Rett syndrome. Additional reports have confirmed a severe phenotype in males with Rett syndrome-associated MECP2 mutations.; DISEASE: Mental retardation, X-linked, syndromic, Lubs type (MRXSL) [MIM:300260]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXSL patients manifest mental retardation associated with variable features. They include swallowing dysfunction and gastroesophageal reflux with secondary recurrent respiratory infections, hypotonia, mild myopathy and characteristic facies such as downslanting palpebral fissures, hypertelorism and a short nose with a low nasal bridge. {ECO:0000269|PubMed:16080119}. Note=The disease is caused by mutations affecting the gene represented in this entry. Increased dosage of MECP2 due to gene duplication appears to be responsible for the mental retardation phenotype.; 	0.43937	0.69428	-0.885424753	10.4623732	83.03146	1.93651	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	109	59	chrX	153287314	chrX:153287314	TG	T	109	PASS	AN=2;DP=59	GT	0/1
